Clinical Drug Investigation

, Volume 32, Issue 12, pp 805–815 | Cite as

Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload

A UK Perspective
  • Jonathan Karnon
  • Keith Tolley
  • Joao Vieira
  • David Chandiwana
Original Research Article

Abstract

Background and objectives

Regular blood transfusions for beta-thalassaemia patients lead to the accumulation of iron deposits in the body. In order to remove such deposits, iron chelation therapy is required. Subcutaneously administered deferoxamine has been the gold standard chelation therapy for over 40 years. Deferasirox is a newer chelation therapy that is taken orally once daily. The objective of this study was to estimate the long-term costs and quality-adjusted life-years (QALYs) associated with deferoxamine and deferasirox in a cohort of transfusion-dependent beta-thalassaemia patients from a UK health service perspective.

Methods

A 50-year annual cycle state transition model comprised three core health states: alive without cardiac complications, alive with cardiac complications, and dead, as well as representing other chronic complications of iron overload: diabetes, hypogonadism, hypoparathyroidism and hypothyroidism. The model was calibrated to identify sets of convergent input parameter values that predicted observed overall survival by mean lifetime compliance with chelation therapy. A pivotal non-inferiority trial informed the main estimates of the effectiveness of deferasirox, which were applied to the calibrated model. Using cost values for the year 2011, costs and utilities were summed over patients’ lifetimes to estimate lifetime costs and QALY gains.

Results

Mean lifetime treatment costs for patients receiving deferoxamine were £70,000 higher than deferasirox. Drug acquisition costs were £100,000 higher for deferasirox, but administration costs associated with deferoxamine were £170,000 higher. Higher compliance associated with oral deferasirox administration led to fewer complications. Combined with the quality-of-life effects of an oral mode of administration, an average gain of 4.85 QALYs for deferasirox was estimated. In the base case, deferasirox dominates deferoxamine, i.e., costs less and patients gain more QALYs. The key parameter is the proportion of deferoxamine patients using balloon infusers. Sensitivity analyses showed that even when the proportion of patients using balloon infusers is decreased from 79 to 25 %, the incremental cost per QALY gained remains well under £20,000.

Conclusion

Higher drug acquisition costs for deferasirox are offset by the avoidance of infusion-related equipment costs. Combined with health benefits derived from an oral mode of administration and improved compliance, deferasirox has a high probability of being a cost-effective intervention compared with deferoxamine.

Notes

Acknowledgements

The research study reported in this paper was undertaken to inform a submission to the National Institute for Clinical Excellence in the UK. Authors Karnon and Tolley received research funding provided by Novartis Pharmaceuticals to undertake the reported analysis. Authors Chandiwana and Vieira are employees of Novartis Pharmaceuticals.

References

  1. 1.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574–8.PubMedCrossRefGoogle Scholar
  3. 3.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009;13(1): iii–iv, ix–xi, 1–121.Google Scholar
  4. 4.
    Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739–61.PubMedGoogle Scholar
  5. 5.
    Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118(4):884–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93.PubMedGoogle Scholar
  12. 12.
    Al Jaouni SK. Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA. JKAU Med Sci. 2010;17(1):19–28.Google Scholar
  13. 13.
    Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111(5):349–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Cunningham MJ, Macklin EA, Neufeld EJ. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–29.PubMedCrossRefGoogle Scholar
  16. 16.
    Kwiatkowski JL, Kim H-Y, Thompson AA. Chelation choices and iron burden among patients with thalassemia in the 21st century: a report from the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort [Abstract]. Blood. 2009;114(22):4056.Google Scholar
  17. 17.
    Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121(6):938–48.PubMedCrossRefGoogle Scholar
  18. 18.
    British National Formulary 61, British Medical Journal Publishing Group and Pharmaceutical Press, March 2011.Google Scholar
  19. 19.
    Cappellini MD, Taher A, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and tolerability of deferasirox doses >30 mg/kg/day in patients with transfusion-dependent anaemia and iron overload. In: Abstract 0845, European Haematological Association meeting, Copenhagen, Denmark, 12–15 June 2008.Google Scholar
  20. 20.
    Payne KA, Rofail D, Baladi J-F, Viala M, Abetz L, Desrosiers M-P, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25(8):725–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44(1):49–60.PubMedGoogle Scholar
  22. 22.
    Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract. 1997;44(6):545–55.PubMedGoogle Scholar
  23. 23.
    Mansel R, on behalf of the ATAC Trialist’s Group. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in 245 postmenopausal women with early breast cancer: a UK National Health Service perspective. In: 29th European Society for Medical Oncology, Vienna Austria, 29th October–2nd November, 2004.Google Scholar
  24. 24.
    Curtis L, Netten A. Unit costs of health and social care, 2005. The University of Kent, Personal Social Services Research Unit.Google Scholar
  25. 25.
  26. 26.
    Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102.PubMedCrossRefGoogle Scholar
  27. 27.
    ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599–606.PubMedCrossRefGoogle Scholar
  29. 29.
    National Institute for Clinical Excellence, Chronic kidney disease, Costing report Implementing NICE guidance, NICE clinical guideline 73, September 2008, http://www.nice.org.uk/nicemedia/live/12069/42209/42209.PDF.
  30. 30.
    Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: a Systematic Review and Economic Evaluation, 2009, http://www.nice.org.uk/nicemedia/live/11966/47853/47853.pdf.
  31. 31.
    Thalassaemia International Federation, Guidelines for the Clinical Management of Thalassaemia, 2nd revised edition, November 2008, ISBN: 978-9963-623-70-9.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  • Jonathan Karnon
    • 1
  • Keith Tolley
    • 2
  • Joao Vieira
    • 3
  • David Chandiwana
    • 3
  1. 1.University of AdelaideAdelaideAustralia
  2. 2.Tolley Health Economics LtdBuxtonEngland
  3. 3.Novartis PharmaceuticalsCamberleyEngland

Personalised recommendations